Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. One out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 3 points (0.0%) at 15,545 as of Thursday, July 25, 2013, 12:49 PM ET. The NYSE advances/declines ratio sits at 1,346 issues advancing vs. 1,602 declining with 83 unchanged. The Health Care sector currently sits up 0.5% versus the S&P 500, which is unchanged. On the negative front, top decliners within the sector include Humana ( HUM), down 2.3%, Intuitive Surgical ( ISRG), down 2.5%, WellPoint ( WLP), down 1.7%, Bristol-Myers Squibb Company ( BMY), down 1.1% and Baxter International ( BAX), down 1.1%. Top gainers within the sector include Boston Scientific ( BSX), up 11.6%, Vertex Pharmaceuticals ( VRTX), up 2.5%, Amgen ( AMGN), up 1.9%, Celgene Corporation ( CELG), up 1.7% and Biogen Idec ( BIIB), up 1.4%. TheStreet would like to highlight 3 stocks pushing the sector lower today: 3. Sequenom ( SQNM) is one of the companies pushing the Health Care sector lower today. As of noon trading, Sequenom is down $1.41 (-30.1%) to $3.28 on heavy volume. Thus far, 27.5 million shares of Sequenom exchanged hands as compared to its average daily volume of 2.4 million shares. The stock has ranged in price between $3.00-$3.42 after having opened the day at $3.07 as compared to the previous trading day's close of $4.69. Sequenom, Inc., a life sciences company, provides genetic analysis solutions in the United States and internationally. It operates through two segments, Molecular Diagnostics and Genetic Analysis. Sequenom has a market cap of $519.3 million and is part of the drugs industry. Shares are down 4.2% year to date as of the close of trading on Wednesday. Currently there are 8 analysts that rate Sequenom a buy, no analysts rate it a sell, and none rate it a hold. TheStreet Ratings rates Sequenom as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, generally high debt management risk and feeble growth in its earnings per share. Get the full Sequenom Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.